Profound Medical Corp. - common stock (PROF)
Healthcare › Surgical & Medical Instruments & Apparatus
Price History
Feb 9, 2026 — May 13, 2026Investment Snapshot
- Trading 18% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 3/9 — signs of financial weakness
- Loss-making — negative ROE of -69.8%
- Revenue growing at 51% annually
Profound Medical Corp. - common stock (PROF) is a Healthcare company operating in Surgical & Medical Instruments & Apparatus, listed on the NASDAQ , with a market capitalisation of $259 million . Key value metrics: P/E ratio 4.7, P/B ratio 4.37, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 2 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Profound Medical Corp. - common stock — Fundamental Analysis Summary
Profound Medical Corp. - common stock (PROF) is currently trading 18% above its Graham Number of $6.03, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a low trailing P/E ratio of 4.7x.
On financial health, PROF shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and negative return on equity of -69.8% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.12.
StockPik's composite Value Score for PROF is 47/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
PROF reports a high gross margin of 72.7% (sector average: 40.1%) and a negative operating margin of -271.1%.
PROF shows revenue growing at 51% year-over-year, with earnings declining at 53%.